Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Hikma makes and sells generic, branded, and injectable medicines that hospitals, pharmacies, and patients use around the world.
Hikma Pharmaceuticals is a medicine maker that sells three broad things: copycat drugs that are no longer under patent (generics), its own branded medicines, and sterile injectable drugs that hospitals give by needle or IV. Most people never see the name — they just take the pill or get the shot — but Hikma is one of the larger players in this space, with a big presence in the United States, the Middle East and North Africa, and Europe.
The generics business is the volume engine. When a drug's patent expires, Hikma and its rivals rush to sell their own versions, and prices fall fast as more competitors pile in. Hikma makes these medicines in factories and sells them mostly to pharmacies, wholesalers, and hospitals. The branded side, concentrated in the Middle East and North Africa, is the steadier, higher-margin business: Hikma sells its own labeled products in markets where it has built trust and distribution over decades. The injectables arm makes sterile vials and prefilled syringes — the kind of product hospitals rely on for surgery, cancer treatment, and emergencies — where manufacturing quality and reliability matter enormously and the barriers to entry are higher. The way it makes money is simple in principle: manufacture a drug cheaply at scale, get it approved by regulators, and sell it at a price that beats rivals while still turning a profit. In generics, that often means being one of the first to launch a copy of a big drug, because early sellers keep more of the price before the market floods. Hikma has used acquisitions to grow, most notably buying parts of Boehringer Ingelheim's US generics business and, more recently, adding injectable and specialty assets to deepen its hospital portfolio. Those deals brought scale but also debt and the constant risk that a key product loses pricing power.
The big vulnerability is price pressure, especially in the US generics market, where buyers have consolidated and negotiate hard. Hikma's answer is to lean on injectables and branded medicines, which are stickier and less commoditized, and to keep expanding manufacturing capacity. It pays a dividend and has bought back shares at times, returning cash to investors while still investing in new plants and products. For a company most patients never notice, its business boils down to a straightforward bet: make essential medicines reliably and cheaply, and sell enough of them that the thin margins add up.
Saved answer · last researched 15 Nov 2026